[go: up one dir, main page]

MX2010002733A - Terapia de intervalo para el tratamiento de tinnitus. - Google Patents

Terapia de intervalo para el tratamiento de tinnitus.

Info

Publication number
MX2010002733A
MX2010002733A MX2010002733A MX2010002733A MX2010002733A MX 2010002733 A MX2010002733 A MX 2010002733A MX 2010002733 A MX2010002733 A MX 2010002733A MX 2010002733 A MX2010002733 A MX 2010002733A MX 2010002733 A MX2010002733 A MX 2010002733A
Authority
MX
Mexico
Prior art keywords
tinnitus
treatment
interval
interval therapy
therapy
Prior art date
Application number
MX2010002733A
Other languages
English (en)
Inventor
Michael Althaus
Barbara Ellers-Lenz
Tanja Rosenberg
Hernann Russ
Hagen Krueger
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2010002733A publication Critical patent/MX2010002733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invenci?n se refiere a una terapia de intervalo y/o mantenimiento que emplea derivados de 1-amino-alquilciclohexano (por ejemplo, neramexano o una sal farmac?uticamente aceptable del mismo) para el tratamiento de un individuo afligido por tinnitus.
MX2010002733A 2007-09-12 2008-09-10 Terapia de intervalo para el tratamiento de tinnitus. MX2010002733A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US99339607P 2007-09-12 2007-09-12
EP07253630 2007-09-12
US6702608P 2008-02-25 2008-02-25
US6693108P 2008-02-25 2008-02-25
US6708308P 2008-02-25 2008-02-25
EP08004776 2008-03-14
EP08004777 2008-03-14
EP08004778 2008-03-14
PCT/EP2008/007418 WO2009033649A1 (en) 2007-09-12 2008-09-10 Interval therapy for the treatment of tinnitus

Publications (1)

Publication Number Publication Date
MX2010002733A true MX2010002733A (es) 2010-04-09

Family

ID=40451596

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2010002735A MX2010002735A (es) 2007-09-12 2008-09-10 Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
MX2010002733A MX2010002733A (es) 2007-09-12 2008-09-10 Terapia de intervalo para el tratamiento de tinnitus.
MX2010002734A MX2010002734A (es) 2007-09-12 2008-09-10 Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
MX2010002736A MX2010002736A (es) 2007-09-12 2008-09-10 Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010002735A MX2010002735A (es) 2007-09-12 2008-09-10 Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2010002734A MX2010002734A (es) 2007-09-12 2008-09-10 Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
MX2010002736A MX2010002736A (es) 2007-09-12 2008-09-10 Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.

Country Status (21)

Country Link
US (6) US9498450B2 (es)
EP (6) EP2548552B1 (es)
JP (6) JP5612473B2 (es)
KR (4) KR20100052559A (es)
CN (4) CN101835469A (es)
AR (3) AR071728A1 (es)
AT (1) ATE532507T1 (es)
AU (4) AU2008298015B2 (es)
BR (2) BRPI0816712A2 (es)
CA (4) CA2699210A1 (es)
DK (1) DK2200600T3 (es)
ES (5) ES2377253T3 (es)
HR (1) HRP20120046T1 (es)
MX (4) MX2010002735A (es)
PL (1) PL2200600T3 (es)
PT (1) PT2200600E (es)
RU (1) RU2011137131A (es)
SI (1) SI2200600T1 (es)
TW (3) TW200922544A (es)
WO (4) WO2009033649A1 (es)
ZA (4) ZA201001261B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548552B1 (en) * 2007-09-12 2015-11-18 Merz Pharma GmbH & Co. KGaA Titration package for 1-amino-alkylcyclohexanes
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
EP2585049A1 (en) 2010-06-24 2013-05-01 Merz Pharma GmbH & Co. KGaA Neramexane multiple unit dosage form
WO2012098000A1 (en) 2011-01-20 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
EA201692164A1 (ru) * 2014-04-28 2017-03-31 Керин Фармасьютикал Ко., Лтд. Лекарственное средство для лечения пациентов с тиннитусом
EP3138559A4 (en) * 2014-04-28 2017-10-25 Kyorin Pharmaceutical Co., Ltd. Drug for treatment of tinnitus patients
NZ731751A (en) 2014-10-23 2023-07-28 Arena Pharm Inc Method of treating conditions related to the pgi2 receptor
EP3909579A1 (en) * 2015-05-18 2021-11-17 Sensorion Calcineurin inhibitors of the setron family for the treatment of hearing loss
KR101893604B1 (ko) 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
CN105924362B (zh) * 2016-02-05 2018-08-17 上海龙翔生物医药开发有限公司 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
KR102432505B1 (ko) 2017-03-01 2022-08-12 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
WO2019222764A1 (en) 2018-05-16 2019-11-21 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
KR102268893B1 (ko) 2020-01-16 2021-06-24 경북대학교 산학협력단 림노트릭스 속 knua002 균주를 포함하는 난청의 예방 또는 치료용 조성물
CN111477199B (zh) * 2020-04-02 2021-11-30 北京瑞迪欧文化传播有限责任公司 一种嵌入式音乐控制系统
EP4297708A4 (en) * 2021-09-09 2024-08-28 Samsung Electronics Co., Ltd. AUDIO CONTENT DELIVERY MANAGEMENT

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
JPH09504027A (ja) 1993-10-22 1997-04-22 ジェネンテク，インコーポレイテッド ワクチンとしての使用のための抗原のマイクロカプセル化のための方法および組成物
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
AU4424697A (en) * 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
PL193237B1 (pl) * 1997-06-30 2007-01-31 Merz Pharma Gmbh & Co Kgaa Pochodne 1-aminoalkilocykloheksanu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
ATE337292T1 (de) * 2000-04-26 2006-09-15 Warner Lambert Co Trans-n- 4-(4-hydroxyphenyl)cyclohexylö-3- phenylpropionamid als subtyp-selektiver nmda rezeptor antagonist
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
JP2004021734A (ja) 2002-06-18 2004-01-22 Nokia Corp キーパッドおよびキーパッドシステム
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
WO2004022069A1 (en) * 2002-09-06 2004-03-18 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
CA2528622C (en) * 2003-05-27 2010-08-03 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
EP2601937A1 (en) 2004-06-17 2013-06-12 Merz Pharma GmbH & Co. KGaA Drinkable immediate release tablet made with direct compression of memantine or neramexane
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CA2594963A1 (en) * 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
JP2008531726A (ja) * 2005-03-04 2008-08-14 ニューロシステック コーポレイション 改良されたガシクリジン製剤
TWI265036B (en) * 2005-04-29 2006-11-01 Guo-Ming Huang Safety injector and method of operating the same
DE602006018460D1 (de) * 2005-05-18 2011-01-05 Gt Urological Llc Wirkstoffeluierung für implantierbare inkontinenzgeräte
CN1896729A (zh) 2005-07-15 2007-01-17 复旦大学附属中山医院 纳米药物自组装双稳态量子线阵列及其制备方法
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
EP2548552B1 (en) * 2007-09-12 2015-11-18 Merz Pharma GmbH & Co. KGaA Titration package for 1-amino-alkylcyclohexanes
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
AU2009291244A1 (en) * 2008-09-10 2010-03-18 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2012098000A1 (en) * 2011-01-20 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss

Also Published As

Publication number Publication date
US20110086916A1 (en) 2011-04-14
US20170027885A1 (en) 2017-02-02
EP2200598A1 (en) 2010-06-30
CA2699209A1 (en) 2009-03-19
WO2009033649A1 (en) 2009-03-19
MX2010002736A (es) 2010-04-01
ZA201001263B (en) 2011-07-27
JP2014221766A (ja) 2014-11-27
TW200922544A (en) 2009-06-01
JP5784189B2 (ja) 2015-09-24
AR070025A1 (es) 2010-03-10
EP2548552A2 (en) 2013-01-23
EP2203163B1 (en) 2014-08-27
PT2200600E (pt) 2012-02-17
AU2008298015A1 (en) 2009-03-19
ES2604945T3 (es) 2017-03-10
EP2548552B1 (en) 2015-11-18
BRPI0816712A2 (pt) 2016-11-08
JP2010539116A (ja) 2010-12-16
WO2009033650A1 (en) 2009-03-19
JP2014221767A (ja) 2014-11-27
JP5563461B2 (ja) 2014-07-30
ES2510565T3 (es) 2014-10-21
US9498450B2 (en) 2016-11-22
KR20100052556A (ko) 2010-05-19
JP2010539115A (ja) 2010-12-16
EP2386299B1 (en) 2016-07-13
EP2200600A1 (en) 2010-06-30
EP2200600B1 (en) 2011-11-09
CN101801365A (zh) 2010-08-11
US20150018425A1 (en) 2015-01-15
CN101801366A (zh) 2010-08-11
SI2200600T1 (sl) 2012-03-30
JP2010539118A (ja) 2010-12-16
JP5784188B2 (ja) 2015-09-24
EP2386299A2 (en) 2011-11-16
CA2699210A1 (en) 2009-03-19
ZA201001264B (en) 2011-07-27
KR20100052559A (ko) 2010-05-19
BRPI0816690A2 (pt) 2016-11-01
TW200918042A (en) 2009-05-01
AR071728A1 (es) 2010-07-14
EP2200599A1 (en) 2010-06-30
JP5612473B2 (ja) 2014-10-22
AR070026A1 (es) 2010-03-10
KR20100052558A (ko) 2010-05-19
AU2008298015B2 (en) 2012-03-22
ZA201001261B (en) 2011-08-31
WO2009033651A1 (en) 2009-03-19
TW200927087A (en) 2009-07-01
CN101795679A (zh) 2010-08-04
CA2699207A1 (en) 2009-03-19
EP2548552A3 (en) 2013-10-16
CA2699213A1 (en) 2009-03-19
AU2008298018B2 (en) 2012-01-19
US8877814B2 (en) 2014-11-04
AU2008298018A1 (en) 2009-03-19
JP5613053B2 (ja) 2014-10-22
AU2008298017B2 (en) 2012-03-01
US20100298441A1 (en) 2010-11-25
ES2596262T3 (es) 2017-01-05
US20110077304A1 (en) 2011-03-31
US9468610B2 (en) 2016-10-18
AU2008298017A1 (en) 2009-03-19
US20100298440A1 (en) 2010-11-25
HRP20120046T1 (hr) 2012-02-29
MX2010002735A (es) 2010-04-01
AU2008298018C1 (en) 2012-08-16
CN101835469A (zh) 2010-09-15
AU2008298016A1 (en) 2009-03-19
EP2200599B1 (en) 2016-08-31
ZA201001262B (en) 2011-07-27
RU2011137131A (ru) 2013-03-20
MX2010002734A (es) 2010-04-01
JP2010539117A (ja) 2010-12-16
ES2562709T3 (es) 2016-03-07
ATE532507T1 (de) 2011-11-15
PL2200600T3 (pl) 2012-04-30
EP2203163A1 (en) 2010-07-07
ES2377253T3 (es) 2012-03-23
KR20100052557A (ko) 2010-05-19
JP5563460B2 (ja) 2014-07-30
WO2009033652A1 (en) 2009-03-19
EP2386299A3 (en) 2012-05-02
AU2008298016B2 (en) 2012-02-02
DK2200600T3 (da) 2012-01-23

Similar Documents

Publication Publication Date Title
MX2010002733A (es) Terapia de intervalo para el tratamiento de tinnitus.
GEP20146082B (en) Compositions and methods of wnt signaling modulators
MX2011007930A (es) Conjugados de insulina cristalina.
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
UA102673C2 (ru) Применение йота-каррагенана как противовирусного активного ингредиента
TN2011000239A1 (en) Hsp90 inhibitor combinations
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
PL2109602T3 (pl) Pochodne tetracyliny do leczenia zakażeń bakteryjnych, wirusowych i pasożytniczych
MX2010004576A (es) Derivados de pirimidina novedosos.
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
TW201144301A (en) Processes for preparing linezolid
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200942524A (en) Novel aminomethyl benzene derivatives
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
MX2011011109A (es) Formulaciones orales de bendamustina.
TW200942530A (en) Pyridine compounds
WO2010009200A3 (en) Methods for treating oral cavity infections with chlorine dioxide
MY150931A (en) Substituted oxazolidinones and their use
MX2009009490A (es) Profarmacos novedosos.
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal